{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih5c44xyywurwf6hyfd7vq7ksjmd4x64bi2mraylir6cymxffozcm",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mfpul74jv5x2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreig3jat5bl2hi3aoatr6dsiul54sujqlg4cu4qdgn6j2y7a7d5tvyy"
    },
    "mimeType": "image/jpeg",
    "size": 144311
  },
  "path": "/2026/02/25/rare-disease-drug-fda-ebvallo/?utm_campaign=rss",
  "publishedAt": "2026-02-25T17:57:24.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Exclusive",
    "biotechnology",
    "Cancer",
    "FDA",
    "Pharmaceuticals",
    "rare diseases",
    "STAT+"
  ],
  "textContent": "Drugmakers thought they had the FDA's buy-in to approve a therapy to treat a type of cancer that can quickly turn deadly. The agency, however, rejected it.",
  "title": "STAT+: A rare disease drug was approvable, then it wasn’t. Inside a surprise rejection by the FDA",
  "updatedAt": "2026-02-25T17:59:02.000Z"
}